SYM FINANCIAL Corp Acquires Shares of 1,615 Natera, Inc. (NASDAQ:NTRA)

SYM FINANCIAL Corp acquired a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,615 shares of the medical research company's stock, valued at approximately $256,000.

Several other hedge funds and other institutional investors have also modified their holdings of NTRA. SeaBridge Investment Advisors LLC acquired a new position in shares of Natera during the fourth quarter valued at about $2,894,000. Chicago Partners Investment Group LLC acquired a new position in Natera in the 4th quarter valued at approximately $297,000. Caprock Group LLC bought a new stake in shares of Natera in the 4th quarter worth approximately $213,000. Gries Financial LLC acquired a new stake in shares of Natera during the 4th quarter worth approximately $286,000. Finally, Baader Bank Aktiengesellschaft bought a new stake in shares of Natera during the fourth quarter valued at approximately $451,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Insider Activity

In other news, CFO Michael Burkes Brophy sold 43,502 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $176.88, for a total transaction of $7,694,633.76. Following the completion of the sale, the chief financial officer now directly owns 70,629 shares in the company, valued at $12,492,857.52. This represents a 38.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Gail Boxer Marcus sold 2,212 shares of Natera stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $158.53, for a total transaction of $350,668.36. Following the transaction, the director now directly owns 19,386 shares of the company's stock, valued at $3,073,262.58. This represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 311,731 shares of company stock valued at $52,215,659. 7.60% of the stock is currently owned by corporate insiders.

Natera Stock Performance

Shares of NASDAQ NTRA traded down $1.86 during trading hours on Thursday, reaching $175.14. 742,631 shares of the stock were exchanged, compared to its average volume of 1,351,574. Natera, Inc. has a 52 week low of $67.33 and a 52 week high of $183.00. The firm has a market capitalization of $23.12 billion, a price-to-earnings ratio of -99.51 and a beta of 1.66. The stock's fifty day simple moving average is $167.56 and its 200 day simple moving average is $140.02. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same quarter in the prior year, the firm posted ($0.95) EPS. The firm's quarterly revenue was up 63.9% on a year-over-year basis. Sell-side analysts predict that Natera, Inc. will post -1.56 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. StockNews.com downgraded shares of Natera from a "hold" rating to a "sell" rating in a research note on Thursday, November 14th. Robert W. Baird upped their target price on shares of Natera from $120.00 to $160.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. Leerink Partners raised their price target on shares of Natera from $140.00 to $150.00 and gave the stock an "outperform" rating in a research note on Thursday, October 17th. Sanford C. Bernstein raised their price objective on shares of Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a research report on Friday, January 10th. Finally, Piper Sandler upped their target price on shares of Natera from $150.00 to $200.00 and gave the company an "overweight" rating in a research report on Monday, November 18th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $165.88.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.